These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 12641503

  • 1. Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate.
    von Tirpitz C, Klaus J, Steinkamp M, Hofbauer LC, Kratzer W, Mason R, Boehm BO, Adler G, Reinshagen M.
    Aliment Pharmacol Ther; 2003 Mar 15; 17(6):807-16. PubMed ID: 12641503
    [Abstract] [Full Text] [Related]

  • 2. Intravenous ibandronate or sodium-fluoride--a 3.5 years study on bone density and fractures in Crohn's disease patients with osteoporosis.
    Klaus J, Reinshagen M, Herdt K, Adler G, von Boyen GB, von Tirpitz C.
    J Gastrointestin Liver Dis; 2011 Jun 15; 20(2):141-8. PubMed ID: 21725510
    [Abstract] [Full Text] [Related]

  • 3. Bones and Crohn's: no benefit of adding sodium fluoride or ibandronate to calcium and vitamin D.
    Klaus J, Reinshagen M, Herdt K, Schröter C, Adler G, von Boyen GB, von Tirpitz C.
    World J Gastroenterol; 2011 Jan 21; 17(3):334-42. PubMed ID: 21253392
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model.
    Kreck S, Klaus J, Leidl R, von Tirpitz C, Konnopka A, Matschinger H, König HH.
    Pharmacoeconomics; 2008 Jan 21; 26(4):311-28. PubMed ID: 18370566
    [Abstract] [Full Text] [Related]

  • 6. Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease.
    Siffledeen JS, Fedorak RN, Siminoski K, Jen H, Vaudan E, Abraham N, Steinhart H, Greenberg G.
    Clin Gastroenterol Hepatol; 2005 Feb 21; 3(2):122-32. PubMed ID: 15704046
    [Abstract] [Full Text] [Related]

  • 7. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis.
    Thiébaud D, Burckhardt P, Kriegbaum H, Huss H, Mulder H, Juttmann JR, Schöter KH.
    Am J Med; 1997 Oct 21; 103(4):298-307. PubMed ID: 9382122
    [Abstract] [Full Text] [Related]

  • 8. The efficacy and safety of bisphosphonates for osteoporosis or osteopenia in Crohn's disease: a meta-analysis.
    Guo Z, Wu R, Gong J, Zhu W, Li Y, Li N, Li J.
    Dig Dis Sci; 2013 Apr 21; 58(4):915-22. PubMed ID: 23179146
    [Abstract] [Full Text] [Related]

  • 9. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE.
    Chesnut CH, Ettinger MP, Miller PD, Baylink DJ, Emkey R, Harris ST, Wasnich RD, Watts NB, Schimmer RC, Recker RR.
    Curr Med Res Opin; 2005 Mar 21; 21(3):391-401. PubMed ID: 15811208
    [Abstract] [Full Text] [Related]

  • 10. A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease.
    Bartram SA, Peaston RT, Rawlings DJ, Francis RM, Thompson NP.
    Aliment Pharmacol Ther; 2003 Dec 21; 18(11-12):1121-7. PubMed ID: 14653832
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of monthly ibandronate in men with low bone density.
    Orwoll ES, Binkley NC, Lewiecki EM, Gruntmanis U, Fries MA, Dasic G.
    Bone; 2010 Apr 21; 46(4):970-6. PubMed ID: 20060082
    [Abstract] [Full Text] [Related]

  • 12. Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial.
    Soo I, Siffledeen J, Siminoski K, McQueen B, Fedorak RN.
    J Crohns Colitis; 2012 Aug 21; 6(7):777-86. PubMed ID: 22398088
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study.
    Eisman JA, Civitelli R, Adami S, Czerwinski E, Recknor C, Prince R, Reginster JY, Zaidi M, Felsenberg D, Hughes C, Mairon N, Masanauskaite D, Reid DM, Delmas PD, Recker RR.
    J Rheumatol; 2008 Mar 21; 35(3):488-97. PubMed ID: 18260172
    [Abstract] [Full Text] [Related]

  • 14. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
    McClung MR, Wasnich RD, Recker R, Cauley JA, Chesnut CH, Ensrud KE, Burdeska A, Mills T, Oral Ibandronate Study Group.
    J Bone Miner Res; 2004 Jan 21; 19(1):11-8. PubMed ID: 14753731
    [Abstract] [Full Text] [Related]

  • 15. Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation.
    van Bodegraven AA, Bravenboer N, Witte BI, Dijkstra G, van der Woude CJ, Stokkers PC, Russel MG, Oldenburg B, Pierik M, Roos JC, van Hogezand RA, Dik VK, Oostlander AE, Netelenbos JC, van de Langerijt L, Hommes DW, Lips P, Dutch Initiative on Crohn and Colitis (ICC).
    Gut; 2014 Sep 21; 63(9):1424-30. PubMed ID: 24146170
    [Abstract] [Full Text] [Related]

  • 16. Monthly Oral Ibandronate Reduces Bone Loss in Korean Women With Rheumatoid Arthritis and Osteopenia Receiving Long-term Glucocorticoids: A 48-week Double-blinded Randomized Placebo-controlled Investigator-initiated Trial.
    Shin K, Park SH, Park W, Baek HJ, Lee YJ, Kang SW, Choe JY, Yoo WH, Park YB, Song JS, Lee SG, Yoo B, Yoo DH, Song YW.
    Clin Ther; 2017 Feb 21; 39(2):268-278.e2. PubMed ID: 28161119
    [Abstract] [Full Text] [Related]

  • 17. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study.
    Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, Christiansen C, Civitelli R, Drezner MK, Recker RR, Bolognese M, Hughes C, Masanauskaite D, Ward P, Sambrook P, Reid DM.
    Arthritis Rheum; 2006 Jun 21; 54(6):1838-46. PubMed ID: 16729277
    [Abstract] [Full Text] [Related]

  • 18. Low serum and bone vitamin K status in patients with longstanding Crohn's disease: another pathogenetic factor of osteoporosis in Crohn's disease?
    Schoon EJ, Müller MC, Vermeer C, Schurgers LJ, Brummer RJ, Stockbrügger RW.
    Gut; 2001 Apr 21; 48(4):473-7. PubMed ID: 11247890
    [Abstract] [Full Text] [Related]

  • 19. Predictors of Ibandronate Efficacy for the Management of Osteoporosis: A Meta-Regression Analysis.
    Ma Z, Li Y, Zhou M, Huang K, Hu H, Liu X, Xu X.
    PLoS One; 2016 Apr 21; 11(3):e0150203. PubMed ID: 26930292
    [Abstract] [Full Text] [Related]

  • 20. Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women.
    Stakkestad JA, Benevolenskaya LI, Stepan JJ, Skag A, Nordby A, Oefjord E, Burdeska A, Jonkanski I, Mahoney P, Ibandronate Intravenous Study Group.
    Ann Rheum Dis; 2003 Oct 21; 62(10):969-75. PubMed ID: 12972476
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.